Generics now lead the semaglutide market worldwide, pushing brand‑name sales into a tightened niche. Industry trackers note that after a rapid rise in India, sales of generic weight‑loss drugs have stabilised and overall demand has stabilised. Recent research finds the drug’s weight‑loss effect differs widely between users, with some seeing strong results and others minimal change. Novo Nordisk announced a partnership with Vivani to create a extended‑release semaglutide implant that could release the drug over multiple months. The development aims to give the company a new option as generic competitors secure more of the market. Analysts say the implant could alter treatment patterns if clinical trials confirm its safety.